tiprankstipranks
Advertisement
Advertisement

SCYX Stock Latest News

GSK closer to relaunching Brexafemme, says Brookline
The FlyGSK closer to relaunching Brexafemme, says Brookline
5d ago
GSK
SCYX
Scynexis: Buy Rating Reiterated as Rare Disease Pipeline Advances; $32 Price Target Maintained
PremiumRatings
Scynexis: Buy Rating Reiterated as Rare Disease Pipeline Advances; $32 Price Target Maintained
1M ago
SCYX
Scynexis initiates SCY-770 study
PremiumThe Fly
Scynexis initiates SCY-770 study
1M ago
SCYX
SCYNEXIS Shareholders Approve Governance and Equity Plan Changes
PremiumCompany Announcements
SCYNEXIS Shareholders Approve Governance and Equity Plan Changes
1M ago
8K
SCYX
Upcoming Stock Splits This Week (June 1 to June 5) – Stay Invested
PremiumMarket News
Upcoming Stock Splits This Week (June 1 to June 5) – Stay Invested
2M ago
PW
SMX
Scynexis trading halted, news pending
PremiumThe FlyScynexis trading halted, news pending
2M ago
SCYX
SCYNEXIS Stockholders Approve One-for-Eight Reverse Split
Premium
Company Announcements
SCYNEXIS Stockholders Approve One-for-Eight Reverse Split
3M ago
8K
SCYX
Scynexis announces 1-for-8 reverse stock split
Premium
The Fly
Scynexis announces 1-for-8 reverse stock split
3M ago
SCYX
Buy Rating Reaffirmed on Scynexis as Rare Disease Pivot and Strong Cash Runway Support Unchanged $4 Price Target
PremiumRatings
Buy Rating Reaffirmed on Scynexis as Rare Disease Pivot and Strong Cash Runway Support Unchanged $4 Price Target
3M ago
SCYX
Scynexis reports Q1 EPS (42c), consensus (12c)
PremiumThe Fly
Scynexis reports Q1 EPS (42c), consensus (12c)
3M ago
SCYX
Scynexis files to sell 87M shares of common stock for holders
PremiumThe Fly
Scynexis files to sell 87M shares of common stock for holders
3M ago
SCYX
SCYNEXIS Director Steven Gilman Announces Board Retirement
PremiumCompany Announcements
SCYNEXIS Director Steven Gilman Announces Board Retirement
4M ago
8K
SCYX
Scynexis: Strategic Pivot to Rare Disease With ADPKD Asset, Strengthened Balance Sheet, and Antifungal Optionality Support Buy Rating and $4 Target
PremiumRatingsScynexis: Strategic Pivot to Rare Disease With ADPKD Asset, Strengthened Balance Sheet, and Antifungal Optionality Support Buy Rating and $4 Target
4M ago
SCYX
SCYNEXIS Acquires SCY-770, Refocuses on Rare Kidney Disease
Premium
Company Announcements
SCYNEXIS Acquires SCY-770, Refocuses on Rare Kidney Disease
4M ago
8K
SCYX
SCYNEXIS Acquires AMPK Program, Expands Rare Disease Pipeline
Premium
Company Announcements
SCYNEXIS Acquires AMPK Program, Expands Rare Disease Pipeline
4M ago
8K
SCYX
SCYNEXIS Raises $40 Million in Strategic Private Placement
PremiumCompany Announcements
SCYNEXIS Raises $40 Million in Strategic Private Placement
4M ago
8K
SCYX
Poxel announces sale of PXL770 to Scynexis for up to $196M
PremiumThe Fly
Poxel announces sale of PXL770 to Scynexis for up to $196M
4M ago
SCYX
Scynexis completes acquisition of PXL-770 for treatment of kidney disease
PremiumThe Fly
Scynexis completes acquisition of PXL-770 for treatment of kidney disease
4M ago
SCYX
Scynexis announces $40M private placement
PremiumThe Fly
Scynexis announces $40M private placement
4M ago
SCYX
Buy Rating on Scynexis Backed by Strong Cash Runway and Differentiated Next‑Generation Antifungal SCY‑247 Opportunity
PremiumRatingsBuy Rating on Scynexis Backed by Strong Cash Runway and Differentiated Next‑Generation Antifungal SCY‑247 Opportunity
5M ago
SCYX
Scynexis announces first patients dosed in Phase 1 SAD, MAD trial of SCY-247
Premium
The Fly
Scynexis announces first patients dosed in Phase 1 SAD, MAD trial of SCY-247
5M ago
SCYX
Cero Therapeutics appoints Eric Francois to board of directors
Premium
The Fly
Cero Therapeutics appoints Eric Francois to board of directors
6M ago
CERO
SCYX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >